You Make the Call: Is 3 months of anticoagulation enough for a provoked VTE?
This month, Keith McCrae, MD, discusses the appropriate length of anticoagulation for a provoked DVT.
And don't forget to check out next month's clinical dilemma...
How I Teach: Navigating the COVID Classroom
As the COVID-19 pandemic increased rapidly in the U.S. in March and April 2020, the Association of American Medical Colleges (AAMC) released guidance strongly...
How I Treat in Brief: Acute Myeloid Leukemia in the Era of New Drugs
Courtney D. DiNardo, MD, and Andrew H. Wei, MD, review recently approved therapies for acute myeloid leukemia and the treatment challenges they present.
This material...
You Make the Call: Should a pregnant patient with hemochromatosis receive iron?
This month, Tomas Ganz, MD, PhD, discusses the treatment of iron deficiency during pregnancy in a patient with hereditary hemochromatosis.
And don't forget to check...
You Make the Call: Is warfarin recommended for a patient with recurrent coronary artery closure?
This month, Michael Kroll, MD, discusses management of a patient with recurrent coronary artery closure.
And don’t forget to check out next month’s clinical dilemma – send in...
How I Treat in Brief: Anticoagulation in Patients With Obesity
This month, Tzu-Fei Wang, MD, and Marc Carrier, MD, MSc, reviewed anticoagulation strategies for patients who are obese and therefore at risk of venous thromboembolism, atrial...
You Make the Call: Should this patient with DLBCL receive rituximab maintenance after R-CHOP?
This month Ann S. LaCasce, MD, MMSc, discusses whether a patient with high-risk DLBCL should receive rituximab maintenance after R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride,...
How I Teach Professionalism With Ariela Marshall, MD
Ariela Marshall, MD, talks about modeling professional communication for trainees by respecting patients’ and colleagues’ differences in gender identity, culture, ethnicity, sexual orientation, and...
You Make the Call: How would you treat these patients with acute stroke who...
This month Keith R. McCrae, MD, discusses anticoagulation for patients with antiphospholipid antibodies and a history of stroke.
And don't forget to check out next month's...
Demystifying PCR-Based Molecular Monitoring in CML
When imatinib, the first tyrosine kinase inhibitor (TKI), was approved for the treatment of chronic myeloid leukemia (CML) in 2001, the disease’s natural history...
Current Issue
October 2020 Volume 6, Issue 12
This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.